Neurocrine Biosciences
Preço: 159.76Empresa e modelo de negócios
Neurocrine Biosciences is a biopharmaceutical company focused on developing treatments for neurological and endocrine diseases. Its core products include therapies for conditions such as tardive dyskinesia and endometriosis. The company operates primarily in the healthcare sector, with major revenue sources stemming from product sales and collaborations with other pharmaceutical firms. Neurocrine's commitment to innovation is reflected in its robust pipeline of drug candidates aimed at addressing unmet medical needs.
Perfil de investimento
The investment profile of Neurocrine Biosciences is more aligned with growth investors, given its focus on innovative therapies and potential for revenue expansion. The absence of dividends suggests a reinvestment strategy aimed at long-term value creation. Investors may find the stock suitable for a medium to long-term horizon, with moderate liquidity reflecting its market position.
Métricas fundamentais (experimental)
- EPS (TTM) — lucro por ação dos últimos 12 meses, $
- 6.71 OK
- Receita QoQ — crescimento da receita trimestre contra trimestre
- 1.1% ≈
- Surpresa de EPS
- 15.5% melhor que o esperado
- Volatilidade 20d
- 2.1% estável
Acompanhar no portfólio
Gráfico de preço
| Data | Antes | Depois | Motivo |
|---|---|---|---|
| 2026-05-16 02:53 | Manter | Comprar | Strong momentum and positive earnings surprise support growth outlook. |
| 2026-05-08 15:31 | — | Manter | Strong recent performance and positive momentum indicators. |
| 2026-05-07 02:53 | Manter | Comprar | Компания демонстрирует положительную динамику цен на акции в краткосрочной перспективе, а также стабильный рост выручки. Умеренный риск обусловлен волатильностью на рынке и отсутствием дивидендов. |
| Data | Analista | Action | Alvo | Preço na época |
|---|---|---|---|---|
| 2026-06-02 09:07 | Goldman Sachs | Atualizar | — → 213 | 161 |
| 2026-05-21 20:23 | Bernstein | Atualizar | — → 221 | 155.5 |
| 2026-05-06 11:36 | Oppenheimer | Preço-alvo elevado | 220 → 230 | 135.06 |
Nada ainda